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Introduction
About 10-20% of patients with familial Mediterranean
fever (FMF) show an inadequate response to colchicine.
Patients with colchicine-resistant FMF with or without
AA-Amyloidosis can be treated with Interleukin-1
(IL-1)-inhibiting drugs.
Objective
We report our experience in adult patients with colchi-
cine-resistant FMF who were treated with anakinra or
canakinumab.
Patients and methods
Demographic data, clinical and laboratory parameters,
MEFV mutations, patient reported outcomes and physi-
cian global health were analyzed in 15 patients treated
with anakinra or canakinumab.
Results
Within our cohort of 160 adult patients with FMF, we
identified 15 patients (4 female and 11 male) who were
treated with anakinra (n=13) or canakinumab (n=2).
Twelve of 15 patients (80%) were of turkish-armenian
ancestry. The median FMF severity score was 8 (range
5-14). Patients carrying two high-penetrance MEFV
mutations (M694V or M680I) had a severity score of
9 (8/15=53%). Patients with a single high penetrance
mutation had a severity score of 11 (3/15=20%). Four
patients (4/15=27%) had no MEFV mutations and the
FMF severity score was 7.5 (p=0.2). FMF-related AA
amyloidosis was diagnosed in 6 patients (40%) and the
median FMF severity score was 10 compared to a sever-
ity score of 7 in 9 patients without amyloidosis (60%)
(p=0.3). Anakinra was used continuously in 13 patients
and in 2 patients only during attacks. The number of
FMF attacks was significantly reduced by anti-IL1 treat-
ment (p=0.0024). The patient reported health and the
physician reported global health were both improved
significantly (p
Conclusion
IL-1-blocking therapies are well tolerated and effective
in patients with colchicine-resistant FMF. Blocking IL-1
reduced the number and severity of FMF attacks.
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